[
    {
        "question":"So, I just want to understand what's our target for this INR 10,000 crore, don't we need additional stores, or we think we're going to have a much lower run rate this year?",
        "answer":"We have factored about 500 to 600 stores to be added during the year. In Q1, we consciously slowed down the store openings to stabilize the existing ones added in the previous year. However, we are back to our normal store opening rate now, and we expect to add between 500 to 600 stores for the year to achieve the target of INR 10,000 crore.",
        "contexts":[
            "INR 935. So, I think we should be able to reach the target of INR 3,000 crore; very early in the stage to kind of say that we'll not be able to hit. I think INR 622 crore is a decent number for Q1, and we should be meeting our target. This is what I would say at this point of time.",
            "Sanjiv Gupta: So I think it is both the things. First important thing is to ensure that the business is; only those transactions onto the platform are run which are making some economic sense to the business, while also looking into the fact that we have a target in our minds. We did about INR 1,650 crore in the previous year and then obviously, we guided INR 3,000 crore. We did INR 622 crore in Q1 and I think the run rate itself is INR 3,500 crore. And while we tapered down certain volumes in Q1 started March to till end of June. But I think, we've got various other initiatives to ensure that we fill the gap quickly with new set of customers, new offerings and we increase the average order value. In fact, our average order value has also gone up in spite, if you could look at it, INR 845 previous year versus INR 935. So, I think we should be able to reach the target of INR 3,000 crore; very early in the stage to kind of say that we'll not be able to hit. I think INR 622 crore is a decent number for Q1, and",
            "Suneeta Reddy: So Chennai is clearly, is there now in terms of, so people are still traveling to Chennai for quaternary care. What is good is that our Tier 2 hospitals also are doing much better. And there is a 17% growth in Tier 2, which I think is a very good signal for, and it's\n---\nrewarding to see that our geographic footprint and the impact on ROCE has validated this strategy.\n\nShyam Srinivasan: Okay. And my last question, I'll keep it brief. We added, I think, 900 stores last year. We have added 30 stores in the first quarter. So, I just want to understand what's our target for this INR 10,000 crore, don't we need additional stores, or we think we're going to have a much lower run rate this year?",
            "Obul Reddy: We have factored about 500 to 600 stores to be added during the year. Q1, consciously we slowed down because in the Q4 last year, we added about 370, 380 stores. And in the last month of March, about 150 stores. So, we want to give that space to stabilize those stores. And Q1, we are back to our normal store openings, and we expect to be there between 500 stores and 600 stores for the year.\n\nModerator: Thank you. We have the next question from the line of Damayanti Kerai from HSBC. Please go ahead.\n\nDamayanti Kerai: My question is again on Apollo 24\/7. So Sanjiv, you mentioned unit economics are improving, you're reducing losses, etcetera. But GMV growth has been, I'll say, slow compared to what we are expecting in last two quarters. And then earlier, you have set a target to double up GMV in '24 compared to '23 level. So, do you think you can still achieve that or you're focusing more on reducing losses?"
        ],
        "ground_truth":"We have factored about 500 to 600 stores to be added during the year. Q1, consciously we slowed down because in the Q4 last year, we added about 370, 380 stores. And in the last month of March, about 150 stores. So, we want to give that space to stabilize those stores. And Q1, we are back to our normal store openings, and we expect to be there between 500 stores and 600 stores for the year.",
        "file_name":"Apollo Hospitals.pdf"
    },
    {
        "question":"So how should we look at ARPOB growth outlook for, say, next one year to two years?",
        "answer":"The ARPOB growth outlook for the next one to two years appears positive and sustainable, with a focus on maintaining healthy levels.",
        "contexts":[
            "Suneeta Reddy: So just one thing on the ARPOB growth has been over 10% improvement in ARPOB 11%. And this is a function of both case mix and tariff increase. So, I think this year, this 11% is; this INR 57,000 moving to maybe up to INR 60,000 is something that we can sustain. In terms of how do we look at occupancy, I think that is the important question that we have headroom for growth and that in places like Chennai, we're already 41% of total market share. And we see, we are growing this. So, with this, I think it's going to be, as we go forward, this was asked earlier, it's going to be higher occupancy, resulting in higher EBITDA and also higher EBITDA margins coming from the cost, fixed cost being met. And therefore, we are quite confident that, that this is the way forward.",
            "As far as the current year is concerned, we are running at about 13.7% for Q1. I think this will continue to be in this range for Q2. And I don't see any reason that we should be inching up in Q3 or Q4, maybe 10 basis points, 20 basis points here and there. It could be max 14%, if not 13.25% to 13.5%. So, something in between. And I guess, as far as the offline business is concerned, they will continue to be around 12% to 12.5%, only a gap of 100 basis points to 150 basis points. So, I think directionally, all of us should look into these discounts for the rest of the year.\n\n# Damayanti Kerai: So somewhere you said 12% to 14% will be the broader range for discount. Just want to...\n\nSanjiv Gupta: Yes. That's right. Yes.\n\n# Damayanti Kerai: And my last question is, if you can provide, this question is for Suneeta ma'am. Volumes are a bit muted, but you have continued to perform well on ARPOB growth, etcetera. So how should we look at ARPOB growth outlook for, say, next one year to two years?",
            "Damayanti Kerai: Okay. So ARPOB, we should be sustaining at a healthy level. Yes, I'm just clarifying. Okay.\n\nModerator: Thank you. We have the next question from the line of Kunal Dhamesha from Macquarie. Please go ahead.\n\nKunal Dhamesha: So the first one on the 24\/7, it seems that in order to kind of improve the profitability, we have put some filters in terms of our strategy to refine our user base. But how would that have impacted our TAM when we look at what our strategy a year back versus now been? So like how much reduction we would have seen in TAM because of this?\n\nSanjiv Gupta: You're referring to CAC, right, cost of acquisition?\n\nKunal Dhamesha: Not cost of acquisition, just because, let's say, we are putting a filter that below INR 2,000 order you would generally take. In that case, that would also reduce our total addressable market based on the affordability, etcetera, right? So how would TAM calculation would have changed for you?\n\nSuneeta Reddy: It's INR 200.",
            "Transcript of AHEL Q1 FY24 Earnings Call\n\nPage 9 of 14\n---\n# Transcript of AHEL Q1 FY24 Earnings Call\n\nModerator: We have the next question from the line of Lavanya from UBS.\n\nLavanya Tottala: I just wanted to check that healthcare revenue growth is driven by ARPOB largely. But sequentially, our margins are broadly similar for both mature and new hospitals. So why is the ARPOB is not translating to higher margins?"
        ],
        "ground_truth":"In terms of how do we look at occupancy, I think that is the important question that we have headroom for growth and that in places like Chennai, we're already 41% of total market share. And we see, we are growing this. So, with this, I think it's going to be, as we go forward, this was asked earlier, it's going to be higher occupancy, resulting in higher EBITDA and also higher EBITDA margins coming from the cost, fixed cost being met. And therefore, we are quite confident that, that this is the way forward.",
        "file_name":"Apollo Hospitals.pdf"
    },
    {
        "question":"And the transacting user number that you have given for this quarter and\ncomparable quarter, would you be able to share the number for quarter 4?",
        "answer":"In the previous quarter, Q4, the transacting user number was about INR 9.9 lakhs.",
        "contexts":[
            "I think as far as the overall canvas is concerned or a future potential is concerned, I think online business has got a vast thing, in a market. And in a true spirit, omni is actually giving us a larger wallet share of any customer. The Aventus suggested that customers are becoming omni during 30% more wallets share versus when we were not omni. So from the strategy point of view also, it's good to have those set of customers which are chronic, which gives us a high repeat. Our repeat for Q1 has been about 27% versus 21% in the previous year, same quarter. So that is also a very good metric. So, I think we are running into a right direction from the strategy and the execution point of view.\n\nKunal Dhamesha: Sure. And the transacting user number that you have given for this quarter and comparable quarter, would you be able to share the number for quarter 4?\n\nSanjiv Gupta: Which specific number are you looking at it?",
            "Sanjiv Gupta: Which specific number are you looking at it?\n\nKunal Dhamesha: Transacting user, right, which is INR 11.4 lakh, which is what is in returning, transacting user base?\n\nSanjiv Gupta: Yes, that's right. So, in the previous quarter, Q4 if you are referring to, it was about INR 9.9 lakhs.\n\nKunal Dhamesha: And the second question is on the payer mix. I think we have shared that insurance is around 44%. But would we be able to share the other channels as well? And let's say, we have been doing this payer mix refinement for last one year. But let's say, when I look at it from two years to three-year perspective, pre-COVID let's say, FY19 or FY20, how would have our payer mix looked? And from there, how much you would have done in terms of refinement?",
            "# Moderator:\n\nThank you. We have the first question from the line of Harith Ahmad from Avendus Spark.\n\n# Harith Ahmad:\n\nSo, my first question is on Apollo 24\/7. I am looking at the GMV for the quarter, there's an 11% quarter-on-quarter growth. But when I look at the revenue that you've disclosed for the online pharmacy distribution of Apollo 24\/7 segment, there's almost 20% quarter-on-quarter decline. So, can you help us understand this disconnect?\n\n# Sanjiv Gupta:\n\nThanks for the question. My name is Sanjiv, I'll pick up this question. I think there are two important things that have happened in the quarter. And I would first refer to the Q4 earnings call wherein we discussed about that how in the platform we've reduced our discount to sub 15%, and at that point of time, January and February months were the time when the discounts to the pharmacy vertical was as high as about 17% to 18%, and we did bring it down to sub 15%.",
            "Transcript of AHEL Q1 FY24 Earnings Call Page 6 of 14\n---\n# play as more-and-more customers have started transacting on both the platforms, obviously, we have to, at some point of time, rationalize the entire thing looking into the scale, looking into the right time, and this is what we did somewhere in March month, that more-and-more omni players started happening across the channels, and it is to the interest of the customer that we should not confuse him or her with differential pricing, and that is where we curtailed down on our discount. So, this is a good move as far as the customer side is concerned. Obviously, it does give a benefit to the Company."
        ],
        "ground_truth":"So, in the previous quarter, Q4 if you are referring to, it was about INR\n9.9 lakhs.",
        "file_name":"Apollo Hospitals.pdf"
    },
    {
        "question":"When I look at it from two years to three-year perspective, pre-COVID let's say, FY19 or FY20, how\nwould have our payer mix looked? ",
        "answer":"The payer mix in FY19 or FY20, pre-COVID, would have shown self-pay accounting for around 45% of the revenue, while insurance would have been approximately 25% to 28%.",
        "contexts":[
            "Sanjiv Gupta: Which specific number are you looking at it?\n\nKunal Dhamesha: Transacting user, right, which is INR 11.4 lakh, which is what is in returning, transacting user base?\n\nSanjiv Gupta: Yes, that's right. So, in the previous quarter, Q4 if you are referring to, it was about INR 9.9 lakhs.\n\nKunal Dhamesha: And the second question is on the payer mix. I think we have shared that insurance is around 44%. But would we be able to share the other channels as well? And let's say, we have been doing this payer mix refinement for last one year. But let's say, when I look at it from two years to three-year perspective, pre-COVID let's say, FY19 or FY20, how would have our payer mix looked? And from there, how much you would have done in terms of refinement?",
            "A. Krishnan: I think pre-COVID self-pay was almost around 45%. Now if you look at self-pay as a percentage of revenue, it is 40%. Insurance is where we have had significant increase, where it was close to 25% to 28% pre-COVID, that has come to 44% of our revenues now. So clearly, between insurance, private pay and self-pay and private sector, we have almost around 80% of our revenues is coming from that, 80%, 82%.",
            "Suneeta Reddy: The previous year had the RT-PCR test, which was COVID test, and therefore, the OP looked high. But now without COVID, it has grown. On a like-for-like basis, there is growth.\n\nModerator: We have the next question from the line of Shyam Srinivasan from Goldman Sachs.\n\nShyam Srinivasan: Just one on overall occupancy. So, 62%, I know you're comparing with 60% a year ago, but that may have been impacted because of COVID and other stuff. So, I just want to understand the level of occupancy, and this is not only you, right, even other companies, I know there's a seasonal issue here in Q1, but has been below expectations, right? So, is there an element of either pent-up that's not coming back, or you generally think this is just a seasonally slowest quarter in the year and things will pick up? So just a color on yourself as well.",
            "# A. Krishnan: The other thing which has also happened is that if you look at the case mix, the case mix has also improved for the better. We have seen that the Congo case mixes are going up, which is all the high-end cases that we are doing, which is the other reason that ARPOB is high. Secondary care cases have also gone up because, clearly, with the insurance and the payer mix helping us, there is a tailwind in insurance, which we believe is here to stay for the next several years. We have just started seeing the traction in insurance, which is good. So clearly, now we are seeing that a lot of people also are coming for secondary care into the hospital, which is why ALOS is down. So, ALOS being down is also a matter of, even if you look at the overall volume, volume growth is 6%. But if you look at insurance and self-pay, the volume growth is actually 11%. So, we had let go, as you know, last year, by Q4, we had let go of lot of CGHS patients across the system, which is why when you compare Q1 to Q1, you"
        ],
        "ground_truth":"I think pre-COVID self-pay was almost around 45%. Now if you look at self-pay as a percentage of revenue, it is 40%. Insurance is where we have had significant increase, where it was close to 25% to 28% pre-COVID, that has come to 44% of our revenues now. ",
        "file_name":"Apollo Hospitals.pdf"
    },
    {
        "question":"What would be for the split for a previous quarter, like Q4?",
        "answer":"For the previous quarter, Q4, the split for pharmacy was INR 375 crore and diagnostics was INR 42 crore.",
        "contexts":[
            "Sanjiv Gupta: Yes. So, Pharma, we did roughly INR 350 crore for the quarter and diagnostics was roughly INR 30 crore, and the remaining was coming in from consultations and the entire IP\/OP business.\n\nLavanya Tottala: Okay. What would be for the split for a previous quarter, like Q4?\n\nSanjiv Gupta: Q4 for pharmacy was INR 375 crore and diagnostics was INR 42 crore. Diagnostics went up by about 16% to 18% for the quarter. And pharmacy, as I said, in the previous question that we took certain decisions to let go those volumes which are not profitable to the organization and that is the reason we see that gets settled in Q1.\n---\nLavanya Tottala: If I may ask last question, what is the tax rate?",
            "Sanjiv Gupta: Which specific number are you looking at it?\n\nKunal Dhamesha: Transacting user, right, which is INR 11.4 lakh, which is what is in returning, transacting user base?\n\nSanjiv Gupta: Yes, that's right. So, in the previous quarter, Q4 if you are referring to, it was about INR 9.9 lakhs.\n\nKunal Dhamesha: And the second question is on the payer mix. I think we have shared that insurance is around 44%. But would we be able to share the other channels as well? And let's say, we have been doing this payer mix refinement for last one year. But let's say, when I look at it from two years to three-year perspective, pre-COVID let's say, FY19 or FY20, how would have our payer mix looked? And from there, how much you would have done in terms of refinement?",
            "I think as far as the overall canvas is concerned or a future potential is concerned, I think online business has got a vast thing, in a market. And in a true spirit, omni is actually giving us a larger wallet share of any customer. The Aventus suggested that customers are becoming omni during 30% more wallets share versus when we were not omni. So from the strategy point of view also, it's good to have those set of customers which are chronic, which gives us a high repeat. Our repeat for Q1 has been about 27% versus 21% in the previous year, same quarter. So that is also a very good metric. So, I think we are running into a right direction from the strategy and the execution point of view.\n\nKunal Dhamesha: Sure. And the transacting user number that you have given for this quarter and comparable quarter, would you be able to share the number for quarter 4?\n\nSanjiv Gupta: Which specific number are you looking at it?",
            "# Sanjiv Gupta:\n\nYes. So, I think this is how we also internally look into, and if I look at Q1FY24, we (inaudible) GMV about 28%, which was roughly 66% in the same quarter previous year, and Q4 was about 32%. And the target for the current year, which I talked about in the\n\nTranscript of AHEL Q1 FY24 Earnings Call Page 12 of 14\n---\n# Transcript of AHEL Q1 FY24 Earnings Call\n\nPrevious earnings call was also to having between 20% to 22%. This is one thing.\n\nAnd secondly, I think many of the initiatives have started working in the organization, which we had thought through and started executing. We had INR 189 crore of expenses in Q4 and INR 15 crore already we used in Q1, which is down to INR 175 crore and this is a structuralized change. So obviously, INR 60 crore worth of cost deduction has already happened. And as I see July month numbers, I am sure that Q2 numbers are also going to be lesser than INR 175 crore that we see next year during the time."
        ],
        "ground_truth":"Q4 for pharmacy was INR 375 crore and diagnostics was INR 42 crore. Diagnostics went up by about 16% to 18% for the quarter. And pharmacy, as I said, in the previous question that we took certain decisions to let go those volumes which are not profitable to the organization and that is the reason we see that gets settled in Q1.",
        "file_name":"Apollo Hospitals.pdf"
    },
    {
        "question":"If I may ask last question, what is the tax rate?",
        "answer":"The tax rate for the Company is currently operating at around 13.7% for Q1, and it is expected to remain in the range of 12% to 14% for the rest of the year.",
        "contexts":[
            "A. Krishnan: I'll just answer that question, which she actually was raising. The tax rate is 25% overall for the Company. And in the standalone, it is 25%. What happens in consol, you see it at a higher number. That's because there are losses which comes from Apollo HealthCo and Apollo AHLL, where there is no tax, which actually skews the tax rate to close to 32%, but the tax rate at the Company is today operating in the standalone is 25%. So one or two of our subsidiaries is still at that older tax regime, like Bangalore will move into the new taxes next year. And I think the same is the case with Lucknow. So these are the two which are in that older tax regime. They will also move to the newer tax regimes in the coming fiscal year.\n\nModerator: We have the next question from the line of Rishabh Tiwari from Allegro Capital Advisors.",
            "Sanjiv Gupta: Yes. So, Pharma, we did roughly INR 350 crore for the quarter and diagnostics was roughly INR 30 crore, and the remaining was coming in from consultations and the entire IP\/OP business.\n\nLavanya Tottala: Okay. What would be for the split for a previous quarter, like Q4?\n\nSanjiv Gupta: Q4 for pharmacy was INR 375 crore and diagnostics was INR 42 crore. Diagnostics went up by about 16% to 18% for the quarter. And pharmacy, as I said, in the previous question that we took certain decisions to let go those volumes which are not profitable to the organization and that is the reason we see that gets settled in Q1.\n---\nLavanya Tottala: If I may ask last question, what is the tax rate?",
            "As far as the current year is concerned, we are running at about 13.7% for Q1. I think this will continue to be in this range for Q2. And I don't see any reason that we should be inching up in Q3 or Q4, maybe 10 basis points, 20 basis points here and there. It could be max 14%, if not 13.25% to 13.5%. So, something in between. And I guess, as far as the offline business is concerned, they will continue to be around 12% to 12.5%, only a gap of 100 basis points to 150 basis points. So, I think directionally, all of us should look into these discounts for the rest of the year.\n\n# Damayanti Kerai: So somewhere you said 12% to 14% will be the broader range for discount. Just want to...\n\nSanjiv Gupta: Yes. That's right. Yes.\n\n# Damayanti Kerai: And my last question is, if you can provide, this question is for Suneeta ma'am. Volumes are a bit muted, but you have continued to perform well on ARPOB growth, etcetera. So how should we look at ARPOB growth outlook for, say, next one year to two years?",
            "Sanjiv Gupta: Which specific number are you looking at it?\n\nKunal Dhamesha: Transacting user, right, which is INR 11.4 lakh, which is what is in returning, transacting user base?\n\nSanjiv Gupta: Yes, that's right. So, in the previous quarter, Q4 if you are referring to, it was about INR 9.9 lakhs.\n\nKunal Dhamesha: And the second question is on the payer mix. I think we have shared that insurance is around 44%. But would we be able to share the other channels as well? And let's say, we have been doing this payer mix refinement for last one year. But let's say, when I look at it from two years to three-year perspective, pre-COVID let's say, FY19 or FY20, how would have our payer mix looked? And from there, how much you would have done in terms of refinement?"
        ],
        "ground_truth":"The tax rate is 25% overall for the Company. And in the standalone, it is 25%. What happens in consol, you see it at a higher number.",
        "file_name":"Apollo Hospitals.pdf"
    },
    {
        "question":"In the previous quarter, you issued both combined pharmacy EBITDA and someone previously asked that it was not quoted as well as we are expecting some ramp-up from the recently added stores. So if you could please tell the combined pharmacy EBITDA?",
        "answer":"The combined pharmacy EBITDA was impacted by the addition of about 1,000 stores last year, which are expected to break even in the next 2 to 3 quarters. The EBITDA improvement for the combined pharmacy is anticipated to come from increased volumes, cost-cutting measures, and improved profitability from the new stores in the upcoming quarters.",
        "contexts":[
            "Moderator: We have the next question from the line of Rishabh Tiwari from Allegro Capital Advisors.\n\nRishabh Tiwari: In the previous quarter, you issued both combined pharmacy EBITDA and someone previously asked that it was not quoted as well as we are expecting some ramp-up from the recently added stores. So if you could please tell the combined pharmacy EBITDA? And second question is regarding the IndAS impact on the EBITDA, there used to be a slide on this. If you could give a ballpark guidance on that.\n\nObul Reddy: On the combined pharmacy EBITDA, as I explained to you that last year, we added about 1,000 stores, and it will take about 1 year, you know 12 to 15 months for the breakeven. So those higher number of stores contributing to the losses has impacted, and we will be back in the next 2,3 quarters. And...",
            "A. Krishnan: On the IndAS to post-IndAS, I'm sorry, that was a miss in the slide. I think we have not sent that. We will add that and put it back there. I think that's the same number as what was there last quarter, pre-IndAS to post-IndAS, I think INR 30 crore at the Healthcare Services level and INR 20 crore at the AHLL level. We'll put it back out there and that slide, we will add and sent it back. We will upload it on the website. Sorry about that.\n\nRishabh Tiwari: Just a clarification. So, there is no EBITDA improvement on the combined pharmacy.\n\nObul Reddy: So, it will be through the volume and cost-cutting next 2 quarters, and our improved profitability on the new stores.\n\nModerator: We have the next question from the line of Naushad Chaudhary from Aditya Birla Sun Life Asset Management.",
            "Sanjiv Gupta: Yes. So, Pharma, we did roughly INR 350 crore for the quarter and diagnostics was roughly INR 30 crore, and the remaining was coming in from consultations and the entire IP\/OP business.\n\nLavanya Tottala: Okay. What would be for the split for a previous quarter, like Q4?\n\nSanjiv Gupta: Q4 for pharmacy was INR 375 crore and diagnostics was INR 42 crore. Diagnostics went up by about 16% to 18% for the quarter. And pharmacy, as I said, in the previous question that we took certain decisions to let go those volumes which are not profitable to the organization and that is the reason we see that gets settled in Q1.\n---\nLavanya Tottala: If I may ask last question, what is the tax rate?",
            "# Suneeta Reddy:\n\nSanjiv, will you take this or Obul is also here? Obul?\n\n# Obul Reddy:\n\nIn line with our combined business which we have seen, this can still be sustained.\n\n# Harith Ahmad:\n\nYes. So there is obviously, when you're thinking of the post-IndAS margins, there is IndAS benefit as well. And that's, in the past, been around 300 to 350 basis points.\n\n# Obul Reddy:\n\nThis is at the business level.\n\n# Harith Ahmad:\n\nYes. Understood. So when I deduct the IndAS benefit here, the combined pharmacy EBITDA margins are maybe in the 2.5% to 3% range, and this is lower than what we used to have in the past. So, I understand there's a higher level of discounting, but you talked about some additional costs in the front-end pharmacy level in the past, in the last few quarters, how are we tracking on those? And how should we think of margins in the combined pharmacy vertical?\n\n# Obul Reddy:"
        ],
        "ground_truth":"On the combined pharmacy EBITDA, as I explained to you that last year, we added about 1,000 stores, and it will take about 1 year, you know 12 to 15 months for the breakeven. So those higher number of stores contributing to the losses has impacted, and we will be back in the next 2,3 quarters.",
        "file_name":"Apollo Hospitals.pdf"
    },
    {
        "question":"Firstly, on the occupancy side, the target which we have 70%, can we reach and sustain that 70% for the long period of time?",
        "answer":"Yes, the target of reaching and sustaining 70% occupancy for a long period of time is feasible in each of the regions where the target is touched.",
        "contexts":[
            "Moderator: We have the next question from the line of Naushad Chaudhary from Aditya Birla Sun Life Asset Management.\n\nNaushad Chaudhary: Firstly, on the occupancy side, the target which we have 70%, can we reach and sustain that 70% for the long period of time? Or do you think it will be like touch and then plan for a sizable capex?\n\nSuneeta Reddy: No that 70% will not require any capex, but this will take us a little time to get to 70%. We're already trending. Probably, we'll reach close to 70%. But while we do have a target of 70%, we will not be able to deliver it and it will require no capex.\n\nNaushad Chaudhary: No, I'm asking can we sustain; once we reach there, can we sustain 70% for a long period\n\nTranscript of AHEL Q1 FY24 Earnings Call Page 11 of 14\n---\n# Suneeta Reddy:\n\nYes, we can in those regions. So overall, as a Company, maybe not. But I think in each of the regions where we touch 70%, we should be able to sustain.\n\n# A. Krishnan:",
            "Yes, we can in those regions. So overall, as a Company, maybe not. But I think in each of the regions where we touch 70%, we should be able to sustain.\n\n# A. Krishnan:\n\nYes. And to also add on to your point, as we said about the new hospital brands, which we are doing you know the 2,000 beds and INR 3,000 crore over the next 3 years, the first stock of beds are coming in the two regions where we have more than 75% occupied, one is Kolkata and the other is Bangalore, which we are looking at. So these are the 2 that will start off. Then we are looking at Gurgaon, which will follow in the year after that, where again, our occupancy is over 75%. So, we are quite clear about how we are looking at the strategy of expansion. Those are new markets. These will not impact our existing occupancies at all.\n\n# Naushad Chaudhary:\n\nI understand. I'm just trying to understand on the blended level, 70% is doable on a sustainable basis or not, on a blended level?\n\n# A. Krishnan:",
            "# Naushad Chaudhary:\n\nI understand. I'm just trying to understand on the blended level, 70% is doable on a sustainable basis or not, on a blended level?\n\n# A. Krishnan:\n\nYes, at this level, but the new hospitals will take time, right, to get to 70%, any new hospital that would come.\n\n# Suneeta Reddy:\n\nUp to 2026, yes.\n\n# Naushad Chaudhary:\n\nWithout compromising on the future growth.\n\n# Suneeta Reddy:\n\nYes.\n\n# A. Krishnan:\n\nYes.\n\n# Naushad Chaudhary:\n\nAnd lastly, in terms of the scalability of your healthcare business, if you hypothetically think of doubling your healthcare revenue from current base, what are the challenges comes to your mind?\n\n# Suneeta Reddy:",
            "Suneeta Reddy: So, it's definitely picking up. This has happened more in the South; I think we were impacted. It was a very hot summer. It was vacation season. And like I said, travel was restricted to one of our networks, which is Chennai. But I think it is seasonal. And July is looking extremely good. So, it's clearly because of some of the things that happened in the first 3 months.\n\nShyam Srinivasan: When we had an aspiration to reach 70% and over time, 75%. Is there any impediments to reaching that numbers? Or do you think over time, our network will be able to get there? Is there an issue of, say, cannibalization in the sense that people who were earlier traveling to Chennai are no longer able to travel or they're going to another network hospital of yours. Are you seeing those dynamics, which will prevent us from reaching historical high occupancies, you think?"
        ],
        "ground_truth":"No that 70% will not require any capex, but this will take us a little time to get to 70%. We're already trending. Probably, we'll reach close to 70%.",
        "file_name":"Apollo Hospitals.pdf"
    },
    {
        "question":"And lastly, in terms of the scalability of your healthcare business, if you hypothetically think of doubling your healthcare revenue from current base, what are the challenges comes to your mind?",
        "answer":"One challenge that comes to mind when considering doubling healthcare revenue is ensuring that there are enough beds to fill. Additionally, increasing occupancy rates by 20% can significantly boost revenue. Maintaining strong traction in the Hospitals division and continuously monitoring growth plans are crucial for scaling the healthcare business successfully.",
        "contexts":[
            "# Naushad Chaudhary:\n\nI understand. I'm just trying to understand on the blended level, 70% is doable on a sustainable basis or not, on a blended level?\n\n# A. Krishnan:\n\nYes, at this level, but the new hospitals will take time, right, to get to 70%, any new hospital that would come.\n\n# Suneeta Reddy:\n\nUp to 2026, yes.\n\n# Naushad Chaudhary:\n\nWithout compromising on the future growth.\n\n# Suneeta Reddy:\n\nYes.\n\n# A. Krishnan:\n\nYes.\n\n# Naushad Chaudhary:\n\nAnd lastly, in terms of the scalability of your healthcare business, if you hypothetically think of doubling your healthcare revenue from current base, what are the challenges comes to your mind?\n\n# Suneeta Reddy:",
            "# Suneeta Reddy:\n\nI think when we are looking at doubling, yes, we are adding beds to ensure that we have beds to fill. But more importantly, again, it's the fact that we still have, by increasing 20% occupancy, we're actually taking up our revenue by another 40%. So clearly, there is headroom to grow, do have plans. And I think that there is strong traction in the Hospitals division. This quarter should be a very good quarter. And I think you could look at it next quarter.\n\n# Moderator:\n\nWe have the next question from the line of Nitin Agarwal from DAM Capital.\n\n# Nitin Agarwal:\n\nSir, on the 24\/7 in terms of the operating losses, which are really expenses which are there at INR 175 crore for this quarter. I mean what is the relation that we should keep in mind the GMV for these expenses?\n\n# Sanjiv Gupta:",
            "Suneeta Reddy: So Chennai is clearly, is there now in terms of, so people are still traveling to Chennai for quaternary care. What is good is that our Tier 2 hospitals also are doing much better. And there is a 17% growth in Tier 2, which I think is a very good signal for, and it's\n---\nrewarding to see that our geographic footprint and the impact on ROCE has validated this strategy.\n\nShyam Srinivasan: Okay. And my last question, I'll keep it brief. We added, I think, 900 stores last year. We have added 30 stores in the first quarter. So, I just want to understand what's our target for this INR 10,000 crore, don't we need additional stores, or we think we're going to have a much lower run rate this year?",
            "Suneeta Reddy: So, it's definitely picking up. This has happened more in the South; I think we were impacted. It was a very hot summer. It was vacation season. And like I said, travel was restricted to one of our networks, which is Chennai. But I think it is seasonal. And July is looking extremely good. So, it's clearly because of some of the things that happened in the first 3 months.\n\nShyam Srinivasan: When we had an aspiration to reach 70% and over time, 75%. Is there any impediments to reaching that numbers? Or do you think over time, our network will be able to get there? Is there an issue of, say, cannibalization in the sense that people who were earlier traveling to Chennai are no longer able to travel or they're going to another network hospital of yours. Are you seeing those dynamics, which will prevent us from reaching historical high occupancies, you think?"
        ],
        "ground_truth":"I think when we are looking at doubling, yes, we are adding beds to ensure that we have beds to fill. But more importantly, again, it's the fact that we still have, by increasing 20% occupancy, we're actually taking up our revenue by another 40%. So clearly, there is headroom to grow, do have plans. And I think that there is strong traction in the Hospitals division. This quarter should be a very good quarter. And I think you could look at it next quarter.",
        "file_name":"Apollo Hospitals.pdf"
    },
    {
        "question":"And then how should we see the EBITDA percentage improving with relation to GMV over the next couple of years?",
        "answer":"The EBITDA percentage is expected to improve with relation to GMV over the next couple of years as the operating expenses are anticipated to decrease with cost reduction efforts. As the GMV grows, the EBITDA to GMV conversion is projected to increase, leading to a narrowing of losses in the business.",
        "contexts":[
            "Sanjiv Gupta: This is a little tricky. But I think the way we look at it is that whatever level of expenses we have it in the digital segment itself, those expenses we used to, we (inaudible) get out of the (inaudible) or the (inaudible) rate that we have it in, on the GMV. So yes, the expenses have started going down. In the future, depending on which particular vertical we intend to invest, there will be a little bit of delta over there. But otherwise, the thought process that the digital alone itself $1 billion could be able to take care of the expense (inaudible). But as far as the current quarter is concerned, I think we did this one segment being down to INR 175 crore this quarter. And current quarter, which is Q2, I think will also be, let's say, at INR 175 crore for sure.\n\nNitin Agarwal: And if I get last one on that. And then how should we see the EBITDA percentage improving with relation to GMV over the next couple of years?",
            "Nitin Agarwal: So I guess the way to look at this thing is this INR 175 crore number is a top-ish number. It keeps probably coming down with the cost reduction as we go forward. And the EBITDA to GMV conversion, the EBITDA, especially with the GMV growth keeps going up, which starts to; I mean that's how the losses begin to narrow in this business.\n\nSanjiv Gupta: Absolutely. That's the direction that we have started working on, too.\n\nNitin Agarwal: And in the next couple of years, when say the GMV goes to close to $1 billion and all that you talk about, I mean at what level do the operating expenses begin to peak out or sustain at around when you start to get to $1 billion in GMV?",
            "Nitin Agarwal: And if I get last one on that. And then how should we see the EBITDA percentage improving with relation to GMV over the next couple of years?\n\nSanjiv Gupta: I think today, if I look at the margin mix, my margin mix is also steadily going up. It used to be about 6% to 7%, 6.6% of the margin to the revenue in Q1 FY23. It went up to 7%, 9% and 9.7% over the previous quarters. This quarter, it is 10.89%. I think the next 2, 3 years, for sure it is going to be more than (inaudible) %.\n\nModerator: We have the next question from the line of Siddharth, an investor.\n\nSiddharth: So, my question was regarding our associate Company, Indraprastha Medical. So last couple of quarters, we've been seeing improved business performance. So, what has led to this turnaround? Is there any operational changes that we have taken?\n\nSuneeta Reddy: Yes. Clearly, we have got very good doctors onboarded, and this has resulted in better performance and high occupancy.",
            "# Harith Ahmad:\n\nIs this revenue-to-GMV ratio that we should be factoring going forward, around 20%, 30%?\n\n# Sanjiv Gupta:\n\nI think it should be better. What happens is whenever you do a structural change to the business, there is a fall that we see on an immediate basis. July, we witnessed a little bit, but I think August is tracking very well. And I think we should be moving up from this 33% to 35% to 40% in this quarter at least.\n\n# Harith Ahmad:\n\nOkay. Got it. The second question is on your guidance of INR 10,000 crore of revenue and 6% EBITDA margins for the combined pharmacy business. So firstly, I wanted to clarify if this 6% is a post-IndAS margin guidance that we have given.\n\n# Suneeta Reddy:\n\nSanjiv, will you take this or Obul is also here? Obul?\n\n# Obul Reddy:\n\nIn line with our combined business which we have seen, this can still be sustained.\n\n# Harith Ahmad:"
        ],
        "ground_truth":"I think today, if I look at the margin mix, my margin mix is also steadily going up. It used to be about 6% to 7%, 6.6% of the margin to the revenue in Q1 FY23. It went up to 7%, 9% and 9.7% over the previous quarters. This quarter, it is 10.89%. I think the next 2, 3 years, for sure it is going to be more than (inaudible) %.",
        "file_name":"Apollo Hospitals.pdf"
    }
]